文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

危重型COVID-19患者的代谢组学分析:诊断与预后生物标志物的鉴定

Metabolomics Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and Prognostic Biomarkers.
PubMed 文献 · Crit Care Explor · 2020-10-21
一句话结论在危重型COVID-19患者中,精氨酸/犬尿氨酸比值可准确区分COVID-19阳性与健康对照及阴性患者,肌酐/精氨酸比值可准确预测COVID-19相关死亡。

本研究对ICU收治的疑似SARS-CoV-2感染患者进行血浆代谢组学分析,使用直接进样-液相色谱-串联质谱和质子核磁共振测量162种代谢物,并与年龄性别匹配的健康对照比较。结果显示,精氨酸/犬尿氨酸比值区分COVID-19阳性与健康对照的准确率达100%(p=0.0002),区分阳性与阴性患者的准确率达98%(p=0.005)。肌酐和肌酐/精氨酸比值预测COVID-19相关死亡的准确率达100%(p=0.01)。这些代谢标志物有助于ICU床旁识别COVID-19状态和预后分层。

要点

  • 精氨酸/犬尿氨酸比值区分COVID-19阳性患者与健康对照的准确率为100%(p=0.0002)。
  • 精氨酸/犬尿氨酸比值区分COVID-19阳性与阴性ICU患者的准确率为98%(p=0.005)。
  • 肌酐和肌酐/精氨酸比值预测COVID-19相关死亡的准确率均为100%(p=0.01)。
  • COVID-19阳性ICU患者死亡率40%,双侧肺炎比例高于阴性患者。
  • 犬尿氨酸升高、精氨酸、肌氨酸和溶血磷脂酰胆碱降低是区分COVID-19阳性的主要代谢特征。

适用人群与场景

  • ICU收治的疑似SARS-CoV-2感染患者,采用标准化医院筛查方法,在ICU第3天检测阴性(COVID-19阴性)或第10天仍阳性(COVID-19阳性)者纳入。
  • 年龄和性别匹配的健康对照。
  • 排除标准原文未提及。

诊断标准与关键阈值

  • 诊断标准:原文未提及COVID-19的具体诊断标准。
  • 关键阈值:精氨酸/犬尿氨酸比值用于分类,原文未给出具体界值;肌酐/精氨酸比值用于预测死亡,原文未给出具体界值。

处置流程与药物剂量

  • 原文提出可考虑将色氨酸(犬尿氨酸前体)、精氨酸、肌氨酸和/或溶血磷脂酰胆碱作为潜在辅助治疗,但未给出剂量、途径或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:代谢组学分析(病例对照研究),样本量原文未明确给出,单中心三级ICU和学术实验室。
  • 人群:年龄性别匹配的健康对照、COVID-19阳性ICU患者和COVID-19阴性ICU患者;COVID-19阳性患者双侧肺炎更常见,死亡率40%。
  • 干预与对照:无干预,比较各组血浆代谢物浓度(162种代谢物,直接进样-液相色谱-串联质谱和质子核磁共振)。
  • 主要终点结果:精氨酸/犬尿氨酸比值区分COVID-19阳性与健康对照的准确率100%(p=0.0002);区分COVID-19阳性与阴性患者的准确率98%(p=0.005)。
  • 关键次要终点:肌酐和肌酐/精氨酸比值预测COVID-19相关死亡的准确率100%(p=0.01)。
  • 不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:病例对照研究(代谢组学分析)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:单中心、样本量未明确、无外部验证;原文未提及具体局限。

对床旁实践的改变

  • 精氨酸/犬尿氨酸比值和肌酐/精氨酸比值可能有助于ICU床旁识别COVID-19状态和预测死亡风险,但需前瞻性验证。
  • 原文提出色氨酸、精氨酸、肌氨酸和/或溶血磷脂酰胆碱可能作为潜在辅助治疗,但无剂量推荐,不能直接用于临床。
  • 适用人群为ICU疑似SARS-CoV-2感染患者;不适用人群原文未提及。
  • 常见陷阱:原文未提及。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Coronavirus disease 2019 continues to spread rapidly with high mortality. We performed metabolomics profiling of critically ill coronavirus disease 2019 patients to understand better the underlying pathologic processes and pathways, and to identify potential diagnostic/prognostic biomarkers.

DESIGN: Blood was collected at predetermined ICU days to measure the plasma concentrations of 162 metabolites using both direct injection-liquid chromatography-tandem mass spectrometry and proton nuclear magnetic resonance.

SETTING: Tertiary-care ICU and academic laboratory.

SUBJECTS: Patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome coronavirus 2, using standardized hospital screening methodologies, had blood samples collected until either testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative) or until ICU day 10 if the patient tested positive (coronavirus disease 2019 positive).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Age- and sex-matched healthy controls and ICU patients that were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well balanced with the exception that coronavirus disease 2019 positive patients suffered bilateral pneumonia more frequently than coronavirus disease 2019 negative patients. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. Feature selection identified the top-performing metabolites for identifying coronavirus disease 2019 positive patients from healthy control subjects and was dominated by increased kynurenine and decreased arginine, sarcosine, and lysophosphatidylcholines. Arginine/kynurenine ratio alone provided 100% classification accuracy between coronavirus disease 2019 positive patients and healthy control subjects (p = 0.0002). When comparing the metabolomes between coronavirus disease 2019 positive and coronavirus disease 2019 negative patients, kynurenine was the dominant metabolite and the arginine/kynurenine ratio provided 98% classification accuracy (p = 0.005). Feature selection identified creatinine as the top metabolite for predicting coronavirus disease 2019-associated mortality on both ICU days 1 and 3, and both creatinine and creatinine/arginine ratio accurately predicted coronavirus disease 2019-associated death with 100% accuracy (p = 0.01).

CONCLUSIONS: Metabolomics profiling with feature classification easily distinguished both healthy control subjects and coronavirus disease 2019 negative patients from coronavirus disease 2019 positive patients. Arginine/kynurenine ratio accurately identified coronavirus disease 2019 status, whereas creatinine/arginine ratio accurately predicted coronavirus disease 2019-associated death. Administration of tryptophan (kynurenine precursor), arginine, sarcosine, and/or lysophosphatidylcholines may be considered as potential adjunctive therapies.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Fraser DD, Slessarev M, Martin CM, et al. Metabolomics Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and Prognostic Biomarkers. Crit Care Explor. 2020. PMID: 33134953. doi:10.1097/CCE.0000000000000272

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。